Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Thermo Fisher Scientific

Pan-ethnic solution for carrier status research, 6/17

June 2017—Thermo Fisher Scientific released its CarrierScan Assay, a high-throughput, microarray-based assay that provides molecular genetics laboratories with a consolidated and automated single pan-ethnic solution for expanded carrier status research.

Asuragen, Thermo Fisher collaboration, 5/17

May 2017—Asuragen entered into a collaboration agreement with Thermo Fisher Scientific for the development and commercialization of capillary electrophoresis-based in vitro diagnostics. Asuragen will leverage its AmplideX PCR/CE product technologies to develop diagnostic kits for the 3500 Dx Series Genetic Analyzer CS2 instrument.

Clariom assays, 1/17

January 2017—Thermo Fisher Scientific’s two Clariom brand of assays, Clariom D Pico and Clariom S Pico, are designed primarily for translational researchers to accelerate the discovery and validation of complex biomarker signatures derived from coding and noncoding RNA across the whole transcriptome. Based on industry-leading microarray technology, the Clariom Pico assay designs include up-to-date content curated from a large number of public sequence databases, including RefSeq, Noncode, Ensembl, VEGA, lncRNAWiki, and RNA Central, among others.

PCR master mix, 11/16

November 2016—Thermo Fisher Scientific launched the Applied Biosystems TaqPath ProAmp PCR Master Mix. The mixes are developed for high-throughput genotyping and copy number variation protocols requiring accurate results from samples containing PCR inhibitors and are designed to deliver sensitive and reproducible results from genomic DNA targets.

Hydrocodone, Brahms PCT assays, 10/16

October 2016—Thermo Fisher Scientific exhibited its expanded offering of new assays, instruments, and software designed specifically for customers working in research and clinical settings. The Thermo Scientific DRI Hydrocodone assay detects hydrocodone in specimen samples and is FDA 510(k) cleared.

NGS assay, 9/16

September 2016—The Oncomine Lung Cell-Free DNA Assay from Thermo Fisher Scientific is designed to target mutations in non-small cell lung cancer samples derived from circulating cfDNA in blood.

Blood banking centrifuges, 9/16

September 2016—Thermo Scientific introduced two large-capacity blood banking centrifuge models. For regular- to medium-throughput blood processing needs, the Sorvall BP 8 and Heraeus Cryofuge 8 centrifuges provide 6 × 550 mL blood bag capacity and, using the same bucket system, are upgradeable to 8 × 550 mL bags.

Reverse transcriptase kit for RT-qPCR, 7/16

July 2016—Invitrogen SuperScript IV VILO Master Mix from Thermo Fisher Scientific is a cDNA reaction master mix designed for two-step quantitative PCR (RT-qPCR) applications. The master mix format uses variable input, linear output technology and combines optimized buffer conditions with Invitrogen SuperScript IV reverse transcriptase.

Siemens, Thermo Fisher strategic relationship, 6/16

June 2016—In a joint effort to provide customers with an advanced solution for molecular testing, Siemens and Thermo Fisher Scientific announced a strategic relationship that includes the integration of Thermo Fisher Scientific’s real-time PCR system into Siemens’ Versant kPCR Molecular Solution.